About us

We are changing the future of cancer diagnostics

Mitarbeiter:innen der oncgnostics GmbH im bei Laborarbeiten

From Jena. For the world.

The founders and managing directors of oncgnostics GmbH are biologist Dr. Alfred Hansel and biochemist Dr. Martina Schmitz. Their vision was to revolutionize cancer diagnostics to be safe and non-invasive. They also aim to improve existing screening programs and lay the foundation for cancers  which currently have no screening programs. The two scientists founded oncgnostics GmbH in 2012. To realize their vision, they relied on highly informative biomarkers patented by oncgnostics. These are detected using polymerase chain reaction, or PCR for short. Various awards, such as the Thuringian Research Award (2014), the Thuringian Innovation Award (2014 and 2017) and the IQ Innovation Award Central Germany (2017), confirmed the efforts of the founders to develop this technology.

Blick auf die Stadt Jena mit dem Jentower.
Portrait von oncgnostics Geschäftsführerin Dr. Martina Schmitz

With GynTect®, we want to provide women with a genuine and safe option for clarifying abnormal findings in cervical cancer screening. Because every woman is in an individual situation and needs individual solutions.

Portrait von oncgnostics Geschäftsführerin Dr. Alfred Hansel

We have developed GynTect® to combat one of the most common types of cancer in women. We focus on early cancer detection. Because the great opportunity with cervical cancer is that we can detect this cancer in its preliminary stages. Therefor it makes sense: the best way to fight cervical cancer is before it even develops!

Eine Laborantin der oncgnostics GmbH pipettiert unter einem Abzug.

Exceptional results thanks to intensive research

In order to improve cervical cancer screening, a completely new method was needed. We wanted to look directly into the cells  toexamine their DNA. So we determined certain characteristics in the DNA, so-called epigenetic biomarkers, which typically occur in cervical cancer. These biomarkers are detected in what is known as a polymerase chain reaction. These biomarkers are detected in what is known as polymerase chain reaction, also known as PCR.

Various awards, such as the Thuringian Research Award (2014), the Thuringian Innovation Award (2014 and 2017) and the IQ Innovation Award Central Germany (2017), confirmed the efforts of the founders to develop this technology.

Our aim is to detect cancer at an early stage and provide patients with rapid certainty.

You can find out more about us on our company website:

Mit GynTect® möchten Dr. Hansel und Dr. Schmitz die Gebärmutterhalskrebs-Diagnostik revolutionieren.

Picture credits: 
About us: Eberhard Schorr/oncgnostics GmbH
From Jena. Für die Welt: Annett Schmitz
Portraits: Eberhard Schorr/oncgnostics GmbH
Exceptional results due to intensive research: Eberhard Schorr/oncgnostics GmbH
Our aim: Eberhard Schorr/oncgnostics GmbH
Contact: Eberhard Schorr/oncgnostics GmbH; Grit Hiersemann

© 2024 oncgnostics GmbH Jena Germany